Product Reports Resources Pricing Login Book a demo

DarioHealth

Health Tech & Medtech · New York City, United States · Founded 2011 · IPO 2013

Personalized, pocket-sized, all-in-one glucose meter coupled with a robust real time mobile app to manage diabetes quickly, efficiently and accurately MoreLess

DarioHealth Corp. (NASDAQ: DRIO) is a digital therapeutics company that provides a platform for managing chronic health conditions. Founded in 2011 as LabStyle Innovations Corp. in Caesarea, Israel, by Dov Oppenheim and Erez Raphael, the company rebranded to DarioHealth to reflect its broader mission. Erez Raphael, who has served as CEO since 2013, brought extensive experience from the software and e-commerce industries, including co-founding an online retail platform, which shaped his user-centric approach to digital health. His leadership has been pivotal in steering the company from its initial focus on a single product to a comprehensive health platform.

The company's business model has transitioned from a direct-to-consumer (B2C) approach to primarily a business-to-business-to-consumer (B2B2C) model, targeting employers, health plans, and pharmaceutical companies. Revenue is generated through recurring subscription fees for its Software as a Service (SaaS) platform, with a smaller portion coming from initial device sales and direct consumer subscriptions. This strategy aims to reduce user acquisition costs and secure stable, high-margin revenue streams through multi-year contracts. The platform serves a diverse client base, including Fortune 100 employers and major national health plans like Aetna.

DarioHealth offers an integrated suite of solutions that address a range of conditions on a single platform, including diabetes, hypertension, weight management, musculoskeletal (MSK) pain, and behavioral health. The platform combines connected medical devices, such as a blood glucose monitor that plugs into a smartphone, a blood pressure cuff, and the Upright Go S sensor for posture, with a highly-rated mobile application (4.9 stars on the Apple App Store). It leverages AI and billions of data points to deliver personalized insights, targeted interventions, and real-time support from human coaches. This multi-condition approach is a key differentiator, designed to provide holistic care and simplify health management for users.

Significant milestones include receiving FDA clearance for its blood glucose monitoring system in 2015 and going public on the NASDAQ in 2013. The company has expanded its offerings through strategic acquisitions, including Upright (MSK) and wayForward (behavioral health) in 2021, Physimax (computer vision for MSK) in 2022, and Twill (digital-led care) in 2024. These acquisitions have been instrumental in creating a comprehensive platform that addresses physical and mental well-being, including recent expansions into maternal health and GLP-1 support programs.

Keywords: chronic condition management, digital therapeutics, DarioHealth, remote patient monitoring, B2B2C healthcare, diabetes management, hypertension solutions, musculoskeletal health, behavioral health platform, AI in healthcare, health technology, Erez Raphael, digital coaching, employee wellness programs, health plan solutions, connected medical devices, SaaS healthcare, chronic care platform, medication management, GLP-1 support

Valuation $83M
Revenue $26M
Total funding $50–100M

Company overview

DarioHealth company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2011
Headquarters
New York City, United States
Employees
248
Open positions
None listed
Dealroom signal
73.8
Investment activity
4 companies · latest Feb 2024
Capital deployed
Preferred round
ACQUISITION
client focusb2btechnologyArtificial IntelligencetechnologyMachine LearningtechnologyComputer VisiontechnologyConnected Devicesub industryMedical Devicessub industryHealth PlatformsectorPersonal HealthsectorDiabetesbusiness modelManufacturingindustryHealthsectorGeopositioningsectorChronic DiseasesectorCore AI

Valuation & funding

DarioHealth funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Jul 2026 $24M Undisclosed
PRIVATE PLACEMENT NON VCOther financing Sep 2025 $18M Undisclosed
POST IPO DEBTDebt May 2025 $50M Callodine Group · Rand Capital
PRIVATE PLACEMENT NON VCOther financing Jan 2025 $6.8M Undisclosed
PRIVATE PLACEMENT NON VCOther financing Dec 2024 $19M Undisclosed
POST IPO DEBTDebt May 2023 Avenue Capital Group
POST IPO CONVERTIBLEOther financing May 2023 Undisclosed
PRIVATE PLACEMENT VCEquity / VC Jan 2021 Farallon Capital Management · Pura Vida Investments · Nantahala Capital Management
POST IPO EQUITYOther financing Jul 2020 Undisclosed
POST IPO EQUITYOther financing Dec 2019 Undisclosed
Showing 10 recorded eventsUnlock the complete deal history →

Financials

Revenue, earnings and profit over time

Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.

YearRevenueGrowthEBITDAMarginProfitMarginR&D
2026 $22M -2.9% −$20M -91.8% −$33M -150.3% $14M
2025 $22M -17.3% −$37M -164.4% −$42M -186.6% $14M
2024 $27M +32.9% −$62M -230.9% −$43M -158.1% $24M
2023 $20M -26.4% −$50M -245.6% $20M
2022 $28M +34.8% −$52M -189.4%
2021 $21M +170.8% −$73M -355.8%
2020 $7.6M −$30M -398.1%
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

DarioHealth website traffic

Latest recorded traffic for DarioHealth is 12K monthly website visits, down 25% over the last three months. DarioHealth's team grew 4.2% over the past year.

Latest monthly visits12K 3-month web change-25% 1-year team growth+4.2%
Monthly website visits133 observations · Jun 2015–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

DarioHealth compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

DarioHealth's talent

Book a demo to see the people
Team profiled 39 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

9 investors on DarioHealth's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series B+ 4 investors entered at this stage
OurCrowd
Avenue Capital Group
Callodine Group
Rand Capital
Other known 5 additional known investors
Farallon Capital Management
Nantahala Capital Management
Pura Vida Investments
Leo Capital
Phoenix Insurance Company

Global footprint

Where DarioHealth has talent and traffic

Workforce by country
7 countries with
team presence
🇮🇳 India39.3%
🇺🇸 United States20.9%
🇮🇱 Israel20.9%
🇨🇦 Canada1.8%
🇲🇪 Montenegro0.6%
Top 5 of 7 shown

In the news

Latest news about DarioHealth

Recent press, funding announcements, and product moves mentioning DarioHealth — open to read from the original sources.

See all news

Market sentiment

What the market is saying about DarioHealth

An AI-synthesized read of the highest-engagement posts about DarioHealth on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See DarioHealth’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.